NewAmsterdam Pharma Co NV
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
NAMS$19.18+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets
| September 30,2024 | December 31,2023 | |
|---|---|---|
| (In thousands of USD) | ||
| Assets | ||
| Current assets: | ||
| Cash | 422,729 | 340,450 |
| Prepayments and other receivables | 15,145 | 6,341 |
| Total current assets | 437,874 | 346,791 |
| Property, plant and equipment, net | 231 | 46 |
| Operating right of use asset | 493 | 55 |
| Intangible assets | 593 | 170 |
| Long term prepaid expenses | - | 35 |
| Total assets | 439,191 | 347,097 |
| Liabilities and Shareholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | 7,039 | 16,923 |
| Accrued expenses and other current liabilities | 10,580 | 11,398 |
| Deferred revenue, current | 4,495 | 8,942 |
| Lease liability, current | 240 | 60 |
| Derivative warrant liabilities | 18,901 | 12,574 |
| Total current liabilities | 41,255 | 49,897 |
| Deferred revenue, net of current portion | - | 1,019 |
| Lease liability, net of current portion | 266 | - |
| Derivative earnout liability | 18,808 | 7,788 |
| Total liabilities | 60,329 | 58,704 |
| Commitments and contingencies (Note 10) | ||
| Shareholders' Equity (deficit): | ||
| Ordinary shares, €0.12 par value; 400,000,000 shares authorized; 92,165,605 and 82,469,768 shares issued and outstanding as at September 30, 2024 and December 31, 2023, respectively | 11,435 | 10,173 |
| Additional paid-in capital | 829,399 | 590,771 |
| Accumulated loss | (466,394) | (316,973) |
| Accumulated other comprehensive income | 4,422 | 4,422 |
| Total shareholders' equity | 378,862 | 288,393 |
| Total liabilities and shareholders' equity | 439,191 | 347,097 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.